Neuropsychopharmacology
November 20, 2020
Felix Müller, Friederike Holze, Patrick C. Dolder et al.
43 citations
Abstract It has been reported that serotonergic hallucinogens like lysergic acid diethylamide (LSD) induce decreases in functional connectivity within various resting-state networks. These alterations were seen as reflecting specific neuronal effects of hallucinogens and it was speculated that these shifts in connectivity underlie the characteristic subjective drug effects. In this study, we...
Psychological Medicine
November 4, 2020
Simon B. Goldberg, Benjamin Shechet, Christopher R. Nicholas et al.
66 citations
Abstract Background Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychological effects of these substances outside the period of acute intoxication have not been fully characterized. This study aimed to: (1) quantify the effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the...
Acta Psychiatrica Scandinavica
October 30, 2020
Kristoffer Andreas Aamodt Andersen, Robin Carhart-Harris, David Nutt et al.
352 citations
Abstract Objective To conduct a systematic review of modern‐era (post‐millennium) clinical studies assessing the therapeutic effects of serotonergic psychedelics drugs for mental health conditions. Although the main focus was on efficacy and safety, study characteristics, duration of antidepressants effects across studies, and the role of the subjective drug experiences were also reviewed and...
Yale University Press eBooks
October 27, 2020
Russell Crandall
This chapter focuses on psychedelics as another emerging front in the war over the war on drugs in the mid 2010s, with most psychedelic substances, such as LSD, mescaline, and psilocybin, being Schedule I listed since 1970. It explains how the scheduling imposed significant barriers to scientific research on hallucinogenic substances and their effects, through stringent security requirements,...
Journal of Psychopharmacology
October 8, 2020
Yasmin Schmid, Peter Gasser, Peter Oehen et al.
82 citations
Background: Lysergic acid diethylamide (LSD) and 3,4-methylenedioxymethamphetamine (MDMA) were used in psychotherapy in the 1960s–1980s, and are currently being re-investigated as treatments for several psychiatric disorders. In Switzerland, limited medical use of these substances is possible in patients not responding to other treatments (compassionate use). Methods: This study aimed to...
Journal of Psychopharmacology
October 8, 2020
Rotem Petranker, Thomas Anderson, Larissa J. Maier et al.
57 citations
Background: Microdosing psychedelics is the practice of taking small, sub-hallucinogenic doses of lysergic acid diethylamide or psilocybin-containing mushrooms. Despite its surging popularity, little is known about the specific intentions to start microdosing and the effects of this practice. Aims: First, we aimed to replicate previous findings regarding the subjective benefits and challenges...
ACS Chemical Neuroscience
October 6, 2020
Genís Ona, Rafael G. Dos Santos, Jaime E. C. Hallak et al.
12 citations
Research with psychedelic drugs has mainly focused on isolated compounds. However, this approach is challenged by the "polypharmacology" paradigm. In this Viewpoint, we suggest that we may be missing something if we do not use the whole product in the case of ayahuasca or Psilocybe mushrooms. After describing how research on psychedelic drugs can be effectively combined with the...
Neuroscience & Biobehavioral Reviews
October 5, 2020
Genís Ona, José Carlos Bouso
59 citations
Microdosing psychedelic drugs-that is, taking sub-behavioral doses of lysergic acid diethylamide (LSD) or psilocybin-is a growing practice in Western societies. Taken mainly for creative or mood-enhancing purposes, thousands of users are increasingly being exposed to (micro)doses of psychedelic drugs. In this systematic review, we searched the available evidence from human studies, focusing our...
American Journal of Management
October 2, 2020
Lawrence Silver
2 citations
There is a long history of psychedelic use throughout history. A great deal of research was conducted on the possible benefits of psychedelics until LSD and psilocybin became street drugs in the 1960s with reported negative effects. Declared illegal in the late 1960s, research slowed on the benefits of such drugs. A new version of the “street” use of psychedelics has emerged in the form of...
Journal of Mental Health Counseling
October 1, 2020
Russ Curtis, Lisen C. Roberts, Elizabeth Graves et al.
28 citations
Psychedelics (i.e., ketamine, methylenedioxymethamphetamine, psilocybin) have been effectively used globally for centuries to treat mental health and addiction issues. However, in the 1950s–1970s, a number of factors, including misuse, abuse, and poorly conceptualized and conducted clinical trials, caused the Federal Drug Administration to classify most of the psychedelic substances as having...